ADMA

Adma Biologics

8.95

+0.34+3.95%

After Hours: 9.03 +0.08 +0.88%19:45 07/02 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE8.70/8.61

TODAY RANGE8.66-9.01

VOL4.37M

MARKET CAP2.07B

52 WEEK RANGE7.21-20.46

AVG VOL (3M)5.23M

% TURNOVER1.88%

TURNOVER--

P/E (TTM)13.19

% RANGE4.07%

EPS(TTM)0.6785

P/E(FORWARD)10.91

P/B5.33

BVPS1.680

DIVIDEND--

P/S4.173

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP2.01B

SHARES OUTSTANDING231.77M

NEXT EARNINGS08/04-08/10

FREE FLOAT224.85M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

PR Newswire·1d ago
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
PR Newswire·2d ago
ADMA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
PR Newswire·2d ago
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire·3d ago
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire·3d ago
ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline
PR Newswire·4d ago
ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
PR Newswire·4d ago
$ADMA Notification: ADMA Biologics Accused of Misrepresentations about its Revenue Sources in Securities Fraud Class Action
PR Newswire·5d ago
ADMA INVESTOR NOTICE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR Newswire·06/26 22:00
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire·06/25 16:00
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire·06/25 09:24
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Seeking Alpha·06/24 14:10
10 mid-cap U.S. healthcare stocks with the weakest momentum grades
PR Newswire·06/23 23:33
Robbins LLP Urges ADMA Stockholders Who Lost Money Investing in ADMA Biologics, Inc. Contact the Firm for Information About Leading the Class Action
PR Newswire·06/23 19:22
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire·06/23 10:43
ADMA Class Notice: ADMA Biologics Investors that Suffered Losses are Notified of the Imminent August 10 Securities Class Action Deadline

Same Industry

Name/Symbol

Change%

Price

ADMA

McKesson

MCK

-0.08%

746.90

Biogen Inc

BIIB

+6.97%

216.03

Amgen Inc

AMGN

+3.47%

373.86

SHPG

CELG-RT

Lilly Eli & Co

LLY

+1.81%

CELG

Therapeuticsmd Inc

TXMD

+3.94%

2.110

JNJ

Abbvie Inc

ABBV

+3.39%

259.57

Zoetis Inc

ZTS

+2.84%

74.51

Gilead Sciences Inc

GILD

+4.21%

131.27

NVO

Bristol-Myers Squibb Co

BMY

+0.66%

57.90

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

-1.19%

24.08

Sanofi FR

SNY

+2.75%

42.95

GCVRZ

NVS

RDY

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.